Healthy adults
Conditions
Interventions
Ingestion of 100g of yogurt drink containing Lactobacillus gasseri SBT2055 daily for 4 weeks prior to influenza vaccination and for 12 weeks after vaccination.
Ingestion of 100g of yogurt drink witho
Sponsors
Hokkaido Information University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Subjects who plan to get inoculated with influenza vaccine in the current financial year. 2.Subjects who agree to participate in the current study with written informed consent.
Exclusion criteria
Exclusion criteria: 1.Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal, endocrine or metabolic disorders or affected with an infectious disease which is required to report to the authorities. 2.Subjects who are suspected to have acute infection such as influenza, etc. 3.Subjects who are under treatment for chronic inflammatory diseases, autoimmune diseases or allergies, etc. 4.Subjects who were vaccinated within 12 weeks prior to participating this study. 5.Subjects who have had anaphylactic reaction, etc. to influenza vaccine in the past. 6.Subjects who have a major surgical history such as gastrectomy, gastrorrhaphy, enterectomy or other serious gastrointestinal surgeries. 7.Pre- or post-menopausal women having complaints of obvious physical changes. 8.Subjects with unusually high or low blood pressure, or with abnormal hematological data. 9.Subjects with serious anemia. 10.Subjects with a history of allergy to medicine or food (especially dairy products, eggs or chicken meat). 11.Subjects who regularly take drugs which may affect the immune function Chinese herbal medicine, health food or supplements (mushrooms, seaweed, nucleic acids, yeast, lactobacillus, etc.) 12.Subjects who regularly take drugs for constipation or diarrhea. 13.Subjects who regularly take the products such as "Megumi Yogurt" "Megumi Drink Type" "Megumi 0 Fat" or other yogurt products from Megumi series of MEGMILK SNOW BRAND Co., Ltd. 14.Heavy smokers, alcohol addicts or subjects with irregular lifestyle. 15.Subjects who donate either 400ml whole blood within 12 weeks or 200ml whole blood within 4 weeks or blood component within 2 weeks prior to this study. 16.Subjects who are pregnant or expected to be pregnant, or lactating during the study. 17.Subjects who participate in other clinical trials within the last one month prior to this study. 18.Any other medical reasons judged by the principal investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Antibody titers to influenza vaccine | — |
Secondary
| Measure | Time frame |
|---|---|
| Natural Killer cell activity , leukocyte differential count, flow cytometric lymphocyte subset analysis , salivary sIgA, MIF, urinary 8-OHdG, produced IFN- alpha /beta by PBMC, expression level of antiviral mRNA in PBMC, proliferative capacity of T cells, frequency of occurrence of cold-like symptoms, plasma IgG and IgA | — |
Countries
Japan
Contacts
Public ContactDir. Prof. Jun NISHIHIRA, M.D., Ph.D.
Hokkaido Information University Health Information Science Center
Outcome results
None listed